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Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that is associated with
the most common type of dementia and is characterized by the presence of deposits
of the protein fragment amyloid beta (Aβ) in the brain. The natural product mixture
of curcuminoids that improves certain defects in innate immune cells of AD patients
may selectively enhance Aβ phagocytosis by alteration of gene transcription. In this
work, we evaluated the protective effects of curcuminoids in cells from AD patients by
investigating the effect on NF-κB and BACE1 signaling pathways. These results were
compared to the gene expression profile of the clearance of Aβ. The minor curcumin
constituent, bisdemethoxycurcumin (BDC) showed the most potent protective action to
decrease levels of NF-κB and BACE1, decrease the inflammatory cascade and diminish
Aβ aggregates in cells from AD patients. Moreover, mannosyl-glycoprotein 4-beta-N-
acetylglucosaminyltransferase (MGAT3) and vitamin D receptor (VDR) gene mRNAs
were up-regulated in peripheral blood mononuclear cells from AD patients treated with
BDC. BDC treatment impacts both gene expression including Mannosyl (Beta-1,4-)-
Glycoprotein Beta-1,4-N-Acetylglucosaminyltransferase, Vitamin D and Toll like receptor
mRNA and Aβ phagocytosis. The observation of down-regulation of BACE1 and NF-κB
following administration of BDC to cells from AD patients as a model system may have
utility in the treatment of asymptomatic AD patients.
Keywords: Alzheimer’s disease, curcumins, next generation sequencing, NF-κB, amyloid beta, mannosyl-
glycoprotein 4-beta-N-acetylglucosaminyltransferase
INTRODUCTION
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that represents the most
common type of dementia. AD is characterized by the presence of deposits of the protein
fragment amyloid beta (Aβ) and twisted fibers of the protein tau (tangles) in the brain
(McKhann et al., 1984; Selkoe, 2001; Blennow et al., 2006). The disproportionate accumulation
and aberrant aggregation of Aβ is associated with the onset of neurodegenerative processes.
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Medications available to treat AD address symptomatic issues
and target glutamatergic and cholinergic neurotransmissions
and often show only modest clinical benefits (Kumar et al.,
2015). Recent achievements in clinical trials of novel disease-
modifying drugs such as aducanumab, show that targeting Aβ
clearance represents a promising strategy in prevention and
treatment of AD (Panza et al., 2016). Aducanumab decreased Aβ
accumulation and slows cognitive decline in subjects during early
stages of AD or in mild cognitive impairment patients (Panza
et al., 2016). In addition to drugs, the study of naturally occurring
compounds may offer promise for a novel therapeutic approach
to treat AD.
Curcumin [i.e., 1,7-bis(4-hydroxy-3-methoxyphenyl)-
1,6-heptadiene-3,5-dione, Compound 3] is a polyphenolic
compound derived from the dried rhizome of the plant Curcuma
Longa (Anderson et al., 2000). In animal studies, curcumin has
been shown to possess neuroprotection biological properties
due to its anti-inflammatory and anti-oxidant effects (Aggarwal
and Harikumar, 2009; Cashman et al., 2012). Curcumin was
reported to promote in vivo disaggregation of existing Aβ
deposits and avoid new aberrant Aβ aggregation into fibrils
(Zhang et al., 2006). However, clinical utility of curcumin has
been limited because of its poor systemic bioavailability and
chemical instability. Ahmed et al. (2010) described the effects
of intraperitoneally injected curcuminoid mixtures [curcumin,
bisdemethoxycurcumin (BDC) and demethoxycurcumin]
and individual components on memory enhancement in an
amyloid-infused rat model. The study found that, compared to
curcumin, BDC (Compound 1) and demethoxycurcumin exerted
a more efficacious effect on memory enhancement.
It may be that regulation of transcription factors, cytokines
and enzymes associated with NF-κB functional activity is
responsible for the mechanism of action of natural curcumins
and analogs to human cells of relevance to AD (Fiala et al., 2007).
In particular, BDC appears to be the most efficient compound
in enhancing macrophage-promoted phagocytosis and Aβ
clearance (Fiala et al., 2007). BDC could have anti-inflammatory
action related to the NF-κB transcription pathway by promoting
over-expression of MGAT3 (GnT-III) and Toll-like Receptors
(TLRs), both known to be essential for normal macrophage
function usually decreased in subjects with AD (Fiala et al., 2007).
In fact, it was amply shown that lipopolysaccharide (LPS) binds
to TLR4, and leads to the activation of NF-κB signaling and to
activation of macrophages (Taro and Akira, 2007). Moreover, the
implication of NF-κB and TLR4 in innate immunity and its link
to phagocytosis by MGAT3 was described previously (Fiala et al.,
2010).
In our previous study (Gagliardi et al., 2012) synthetic
curcumin derivatives and other molecules (i.e., 45 compounds)
were tested in an in vitro model of AD (i.e., monocytic cell
lines, U-937, THP-1). It was shown that BDC stimulated the
Vitamin D receptor (VDR) gene and had immunostimulatory
effects such as regulating the transcription of genes implicated
in innate immunity. VDR could act by protecting neurons
from Aβ-induced toxicity and improving phagocytosis and Aβ
degradation by promoting monocyte/macrophage maturation.
Moreover, Liu et al. (2010) showed that curcumins may
significantly suppress BACE1 mRNA in cells from AD patients
and confirmed the action of curcumins on gene expression.
The aim of the present work was to evaluate the protective
effects of curcuminoids in blood cells from AD patients.
Accordingly, we investigated the effect of several curcuminoids
(Gagliardi et al., 2012) on NF-κB gene expression and compared
the result to the clearance of Aβ in cells from AD patients.
Numerous papers have reported effects of curcuminoids on
cellular lines and animal models (Gagliardi et al., 2012), but few
reports are available about their effect on primary cells from
AD patients. To address this, we investigated the efficacy of
curcuminoids on peripheral blood mononuclear cells (PBMCs)
from AD patients and compared the results with matched control
cells. Human PBMCs appear to be a good model system to study
neurodegenerative processes because they have been shown to
share much of the non-synaptic biochemical environment of
neurons as well as signaling pathways of the (CNS’s) immune
cells (Gagliardi et al., 2013; Arosio et al., 2014). In this report,
based on results from in vitro cell-based studies with PBMCs,
we describe the identification of a potent curcuminoid that
modulates neurodegenerative signaling pathways in vitro. The
results may be of relevance for future clinical studies aimed
at increasing the clearance of Aβ and improving cognitive
impairment.
MATERIALS AND METHODS
AD Patients and Healthy Volunteers
Clinical and neurological examinations of AD patients were
conducted at the IRCCS Mondino Foundation (Pavia, Italy).
Healthy volunteers were recruited to the Immunohematological
and Transfusional Service and Centre of Transplantation
Immunology (IRCCS Foundation “San Matteo,” Pavia, Italy).
Peripheral blood samples were collected from 30 AD patients
with no family history of dementia and 28 healthy volunteers
over 65 years of age after obtaining written informed consent
(Table 1). Before being enrolled, the subjects that participated
in the study signed an informed consent form (Protocol
n◦375/04 – version 07/01/2004). AD diagnosis was made
according to the National Institute of Neurological and
Communicative Disorders and Stroke and the AD and Related
Disorders Association (NINCDS-ADRDA) criteria (Aggarwal
and Harikumar, 2009). Quantification of neuropsychological
TABLE 1 | Characteristics of subjects recruited for this study.
AD CTRs
(n = 30) (n = 28)
Age (M ± SD) 76.3 ± 4.3 75.7 ± 7.4
Sex
Males n (%) 16 (53,3%) 12 (42,8%)
Females n (%) 14 (46.7%) 16 (57,2%)
Values are reported as average ± standard deviation. The percentage of male and
female subjects is also indicated.
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testing, a detailed interview and clinical examinations were
conducted with each subject. The severity of dementia in the AD
patients was evaluated by the Mini Mental State Examination
(MMSE) and carried out in accordance with The Code of Ethics
of the World Medical Association (Declaration of Helsinki).
PBMC Isolation and Treatment
Peripheral blood mononuclear cells were prepared by layering
peripheral blood on Ficoll-Histopaque (density = 1.077) and
centrifugation at 950 × g for 30 min. After isolation on a
Ficoll-Histopaque layer (Sigma, Italy), cell viability was assayed
by a trypan blue exclusion test and by cytometric analysis
(Strober, 2001). Viable cells were used for in vitro studies with
curcumins. PBMCs (5 × 106 cells with viability ≥80%) were
independently treated for 24 h with five different curcumins
(0.1 µM) obtained from the Human BioMolecular Research
Institute in San Diego, CA, United States. The curcumins were
placed in DMSO and administered to cells in media. The five
curcuminoids with the greatest potency for inducing expression
of genes relevant to Aβ phagocytosis were selected based on
results from a previous report (Gagliardi et al., 2012). The
chemical structures of curcumins used in the studies are shown
in Figure 1. About 5 × 106 PBMCs were treated for 24 h with
0.1 µM of each curcuminoid and then with Aβ 1–42 (1 µM)
(Sigma-Aldrich) for an additional 24 h. The conditions for tests
included (Figure 2): untreated, treated only with curcuminoids,
treated only with Aβ and, finally, treated with both curcuminoids
and Aβ.
Cell Viability
Trypan blue exclusion tests were conducted to assay cell viability
after treatments. Curcuminoids and Aβ at 0.001–10 µM were
used to treat PBMCs from AD patients and healthy volunteers
for 24 h. The concentration range was determined based on data
from similar studies carried out in different experimental models
(Gagliardi et al., 2012).
High-Performance Liquid
Chromatography (HPLC)
To confirm the presence/absence of intact curcuminoids in
cell culture supernatants and cell pellets, an HPLC method
with ultraviolet (UV) detection for the determination of the
selected compounds was used. A 1000 µL aliquot of cell culture
supernatant was introduced onto an EMPORE Extraction
Disk Cartridge (Sigma-Aldrich) under vacuum at 15 in Hg.
Cartridges were conditioned sequentially with 1000 µL of
methanol and 1000 µL of water. Interfering substances were
washed out with water (1000 µL). Analytes were eluted with
acetonitrile (80 µL) and water (120 µL). The eluate was
then centrifuged at 1500 × g for 5 min at 4◦C and 50 µL
was injected onto the HPLC system. HPLC analyses were
carried out using a Shimadzu LC-10Av chromatograph
(Shimadzu Scientific Instrument, Inc., Columbia, MD,
United States) equipped with a System Controller SCL-10Avp,
an LP-10ADvp pump, an on-line Degasser DGU-14A, a
SIL-10ADvp auto injector and a model CTOXX temperature
controller. The system was connected to a LaChrom L-7400
variable wavelength detector (Merck, Darmstadt, Germany).
Separation of selected compounds was achieved on a Chromolith
Performance Column (100 mm × 4.6 mm i.d., RP-18e,
Merck, Darmstadt, Germany), protected by a guard column
of the same composition (5-4.6 mm i.d., RP-18e, Merck,
Darmstadt, Germany). The mobile phase was prepared by
adding 1 mL of 85% phosphoric acid to 1 L of a mixture of
water/acetonitrile (60:40 vol/vol) and thoroughly mixed. The
column temperature was maintained at 50◦C and the flow rate
FIGURE 1 | Chemical structures of curcuminoids used for cell treatment.
Frontiers in Pharmacology | www.frontiersin.org 3 December 2018 | Volume 9 | Article 1404
fphar-09-01404 November 29, 2018 Time: 13:6 # 4
Gagliardi et al. Curcuminoids in AD Prevention
FIGURE 2 | Schematic representation of experimental plan.
was 1.5 mL/min. Curcuminoids were detected at 420 nm. Data
were acquired and analyzed using the Shimadzu LabSolution Lite
software.
RNA-Seq
RNA was extracted using the Maxwell 16, Blood kit (Promega and
automated purification system Maxwell 16). RNA was analyzed
by a Bioanalyzer spectrophotometer to verify the quality and the
concentration and stored at−80◦C. RNA libraries were prepared
by TruSeq Targeted RNA Expression NF-κB Panel (Illumina,
United States) according to the manufacturers’ instructions. The
panel was integrated by BACE1 as an AD-linked gene, and VDR
and MGAT3 to confirm the involvement of these two genes
along the lines reported previously (Gagliardi et al., 2012). RNA
processing and RNA-seq analysis was carried out using Illumina
MiSeq sequencer. RNA sequencing data is available in GEO
repository (GSE122438).
Bioinformatics Analysis
Differential gene expression analysis was conducted on data
obtained with TruSeq Targeted RNA Expression Kit with a
MiSeq sequencer. Cells from AD patients and healthy volunteers
were treated with different curcuminoids, both separately and
in combination and were compared to identify differentially
expressed genes.
The tables of counts obtained via MiSeq reporter analysis was
imported in R1 and differentially expressed genes were evaluated
1https://www.r-project.org/
using a negative binomial GLM approach (EdgeR Bioconductor).
Batch effects were removed with the RemoveBatchEffects
function. Differentially expressed genes had | log2FC | > 1 and
p-values <0.1.
To validate the expression profiles obtained by RNA-Seq,
real-time PCR was conducted on MAGT3, VDR, NF-κB, and
BACE1 genes selected for high or low expression levels.
Immunofluorescence Microscopy
1 × 105 cells were placed on a poly-L-lysine slide (Thermo
Fisher Scientific) and incubated at 37◦C to allow cell attachment
to the slide. Cells were rinsed with 1× PBS and fixed in 4%
paraformaldehyde in 1× PBS. Fixed cells were washed with
1× PBS and blocked with 5% normal goat serum in 0.1%
Tween-PBS for 1 h. Incubation with the primary mouse anti-beta
amyloid antibody (1:100 dilution; Abcam) was conducted
in blocking solution overnight at 4◦C. The fluorescently
tagged secondary antibody CFTM 488A goat anti-rabbit
(1:700 dilution; Sigma-Aldrich) was used for detection. Slides
were mounted with Prolong R© Gold anti-fade reagent with
4′6-diamidino-2-phenylindole (DAPI) (Invitrogen) and images
were acquired by confocal microscopy (Leica DM IRBE, Leica
Microsystems Srl, Italy).
AlphaLISA
Immediately after PBMCs were treated with curcumins, they
were centrifuged at 16,000 rpm for 8 min at room temperature
and the cell pellet was incubated with lysis buffer supplemented
with protease inhibitors at 4◦C for 10 min and then centrifuged
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at 18,000 × g for 15 min at 4◦C. The supernatant was used for
measuring Aβ 1–42. The Aβ 1–42 content was determined using
the AlphaLISA technique with the AlphaLISA human amyloid
beta 1–42 (high specificity) kit (PerkinElmer) according to the
manufacturers’ instructions. In the assay, biotinylated antibody
against Aβ 1–42 and Acceptor beads (PerkinElmer) conjugated
to a 2nd antibody against Aβ 1–42 was added to samples in 1×
HiBlock AlphaLISA buffer on the assay plate. One antibody was
specific to the β-secretase cleavage site at the N-terminus (mouse
monoclonal antibody, clone number 82E1), the second antibody
FIGURE 3 | Cell viability. Cell viability was assessed by Trypan Blue exclusion test. PBMCs (Peripheral blood mononuclear cells) were treated with COMPOUND 1 at
0.001–10 µM (A), with amyloid beta (B), with both COMPOUND 1 and amyloid beta (C), and the Time Course for all three treatments (D).
FIGURE 4 | HPLC-UV chromatograms of PBMC samples from AD patients (A, supernatants; B, pellets) and healthy controls (C, supernatants; D, pellets) incubated
in the absence (black, untreated; blue, treated with Aβ) or presence (red, treated with COMPOUND 1 and Aβ; green, treated with COMPOUND 1). COMPOUND 1
10 µM for 24 h at 37◦C in cellular pellets and supernatants.
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was specific to the C-terminus (mouse monoclonal antibody,
clone number 12F4). The plate was sealed and incubated for 1 h
at room temperature. Streptavidin-coated Donor beads were then
added under subdued lighting, followed by 1 h incubation in the
dark to bind the biotinylated antibody. When both antibodies
bound Aβ 1–42 fragments, they were in close enough proximity
and the excitation at 680 nm resulted in the production of 1O2
from the Donor beads. Energy is transferred from the singlet
oxygen to the Acceptor beads, subsequently culminating in light
production at 615 nm that was detected using an EnVision plate
reader (PerkinElmer). For each group of cells, Aβ 1–42 content
was determined by interpolating the standard curve using 4PL
non-linear regression. As a control the same procedure was
conducted with PBMCs treated only with Aβ in the absence
of BDC.
RESULTS
Cell Viability
Cells treated with 10 µM curcumin and 10 µM Aβ showed a
greater decrease in viability compared with lower concentrations
examined. Therefore, curcumins at 0.1 µM and Aβ at 1 µM
were used for experiments (Figures 3A,B). Treatments with both
molecules at the chosen concentrations did not show a significant
alteration of cells viability (Figure 3C).
Analysis of Curcuminoids in
Supernatants and Cellular Pellets
Although 10 µM curcuminoid was the concentration with the
greatest impact on cells viability, the percentage of apoptosis was
considered acceptable (20%) so it was used for HPLC analysis
due to the sensitivity of the method. Under the chromatographic
conditions the duration of each chromatographic run was 8 min
and COMPOUND 1 eluted at 7 min. HPLC analysis conducted
on PBMC samples from AD patients and healthy volunteers
treated with curcuminoids (i.e., 10 µM for 24 h) showed the
presence of compounds in the cellular pellet. Curcumins were
absent in the supernatant of cells from both AD patients and
healthy subjects treated with curcumins (Figures 4A,C). The
presence of curcuminoids in the cellular pellet was reasonable
based on the lipophilicity and protein binding properties of
the compounds and confirmed that they partitioned into cells
(Figures 4B,D).
mRNA Expression Profiles in PBMC
Samples From AD Patients and Healthy
Volunteers
Compared to untreated PBMC cells of AD patients, mRNA
expression of 12 selected genes in PBMCs from healthy controls
showed a significant difference (Table 2). Among the 12 genes
examined, 6 genes (i.e., NF-κB, BACE1, VDR, MGAT3, TLR7, and
TLR8) were previously reported to be targets of curcumin action.
Alterations of NF-κB, BACE1, MGAT3, and VDR gene expression
were validated with Real-Time PCR. The results confirmed the
next generation sequencing (NGS) data that showed an increase
TABLE 2 | Statistically significant differentially expressed mRNAs in PBMCs from
AD patients, compared to controls.
Genes logFC FDR
IFNA1 −5,068413935 0,000490531
TNFSF14 −3,658110471 0,000214144
IL1RN −3,640381192 1,66533E-05
ICAM1 −3,517928503 2,5152E-10
RELB −3,095303227 0,000234517
IRAK1 −3,029891347 4,04098E-06
TRADD −2,854373904 0,000398196
LTBR −2,307780352 2,51562E-06
NFKB2 −2,264966319 0,000398196
IRAK2 −2,200464564 0,000137778
PLAU −2,199648435 0,007553911
VCAM1 −2,155015236 0,016657456
TICAM1 −1,920135409 0,005236392
NFKBIE −1,719026115 0,000234517
MMP9 −1,672886236 0,01143092
TLR9 −1,622129773 0,004608774
TNFRSF1A −1,620666312 0,001389893
TNFAIP3 −1,538997066 0,004768896
IKBKG −1,53268413 0,003992276
CXCL1 −1,397816804 0,081832301
TNFRSF10B −1,312723196 0,000398196
GADD45B −1,311377024 0,006364934
SOD2 −1,268237434 0,005538847
VDR −1,25733448 0,001665746
ELK1 −1,025052967 0,016657456
MGAT3 −0,99923567 0,006115305
XIAP −0,997730728 0,061153047
EGR1 −0,890765445 0,055696396
TLR6 −0,760645822 0,04190734
TNFRSF1B −0,518149337 0,081953512
REL 1,079234282 0,077638505
MYC 1,20491787 0,077638505
CD69 1,482195001 0,027318454
BIRC3 1,494054357 0,01156061
CD27 1,53452282 0,046143966
MALT1 1,882689476 0,022264388
CHUK 2,176330259 0,000748631
BACE1 2,25413641 0,068195351
TLR3 2,995531758 0,000234517
NFKB 3,002989135 0,005755391
Transcripts were considered as differentially expressed when | log2(disease
sample/healthy control) | ≥ 1 and a FDR ≤ 0.1.
of NF-κB and BACE1 in cells from AD patients compared to cells
from healthy volunteers and a decrease of MGAT3 and VDR in
cells from AD patients compared to cells from healthy controls
(Table 2).
Treatment of PBMCs From AD and
Healthy Volunteers With Curcuminoids
Peripheral blood mononuclear cells from AD patients and
healthy volunteers treated with curcuminoids (i.e., 0.1 µM,
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FIGURE 5 | Peripheral blood mononuclear cells from AD patients and control subjects treated with Aβ (48 h) or untreated, COMPOUND 1 (24 h) and COMPOUND 1
(24 h) + Aβ (24 h). (A) Immunohistochemistry images; (B) Aβ Alpha Technology Assays; (C) Deregulated RNAs for PBMCs treated with Aβ and treated with
COMPOUND 1 + Aβ.
FIGURE 6 | MGAT3, NF-κB, BACE1, and VDR gene expression in PBMCs from AD patients and control subjects treated with Aβ (48 h) or untreated, and
COMPOUND 1 (24 h) and COMPOUND 1 (24 h) + Aβ (24 h).
24 h) showed a significant alteration in gene expression in cells
from AD patients (Supplementary Table S1). Compared to cells
from healthy volunteers, COMPOUND 1 was the most potent
compound in regulating genes expression and caused a twofold
increase after treatment in cells from AD patients Compared to
PBMCs from healthy controls, down-regulation of MGAT3 was
observed (log2FC = 18) in untreated PBMCs of AD patients.
In contrast, over-expression of MGAT3 was observed in PBMCs
of AD patients treated with curcuminoids (i.e., 7- and 18-fold
increase with COMPOUND 1 and 3, respectively). This showed
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FIGURE 7 | Peripheral blood mononuclear cells from AD patients and control subjects treated with Aβ (48 h) and untreated, COMPOUND 2 (24 h) and COMPOUND
2 (24 h) + Aβ (24 h). (A) Immunohistochemistry images; (B) Aβ Alpha Technology Assays; (C) Deregulated RNAs between PBMCs treated with Aβ and treated with
COMPOUND 2 + Aβ.
that curcuminoids were able to induce transcription of MGAT3
in PBMCs from AD patients even in the absence of Aβ.
Treatment of PBMCs From AD and
Healthy Volunteers With Aβ
Treatment of PBMCs from AD patients with Aβ 1–42 (1 µM)
caused significant alterations in genes expression but only in
cells from AD patients (Supplementary Table S2). Compared to
untreated PBMC cells from healthy volunteers, results showed
that treatment of PBMCs from AD patients afforded a greater
number of altered genes. Compared to PBMCs from healthy
volunteers, 20 genes were up-regulated in PBMCs from AD
patients after treatment with Aβ (0.1 µM, 24 h). For example,
MGAT3 and VDR were increased log2FC, five and twofold,
respectively. TLR4, 5, 7, and 8 were up-regulated log2FC, X-,
X-, etc-fold, respectively. Compared to PBMCs from healthy
volunteers, 15 genes were down-regulated in PBMCs from AD
patients treated with 0.1 µM for 24 h. For example, CCR5,
CD27, and CD83 genes involved in inflammatory pathway were
down-regulated four-, three-, and twofold log2FC, respectively.
Effect of COMPOUND 1 Treatment on
PBMCs From AD Patients and Healthy
Volunteers
Individual PBMCs from 30 AD patients and 28 healthy volunteers
were treated with COMPOUND 1 (i.e., 0.1 µM, 24 h), and then
Aβ 1 µM was added to the cell culture for the next 24 h and Aβ
and gene expression was quantified.
Aβ Protein Quantification
Immunofluorescence results afforded a qualitative measure of Aβ
in PBMCs. A decrease of green fluorescence in PBMCs from
AD patients in the presence of COMPOUND 1 (0.1 µM, 24 h)
showed a decrease of Aβ (Figure 5A).
An AlphaLISA assay showed a quantitatively and statistically
significant decrease (p < 0.01) of Aβ in PBMCs from AD
patients treated with COMPOUND 1 (Figure 5B). In contrast,
a statistically significant difference was not observed in PBMCs
from healthy volunteers treated with COMPOUND 1 (0.1 µM,
24 h).
Gene Expression
NGS data showed that, compared to PBMCs from healthy
volunteers, treatment of PBMCs from AD patients with
COMPOUND 1 (i.e., 0.1 µM, 24 h) caused transcriptional
changes in 9 genes (Figure 5C). Compared to cells from
healthy volunteers TRL2 and TRL4 were up-regulated (5- and
10-fold, respectively) after treating PBMCs from AD patients
with COMPOUND 1 (0.1 µM, 24 h) based on quantitative RT-
PCR analysis. Compared to PBMCs from healthy volunteers,
treatment of PBMCs from AD patients with COMPOUND
1 (0.1 µM, 24 h) showed a statistically significant increase
(p < 0.01) of genes involved in Aβ clearance (i.e., MGAT3 and
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FIGURE 8 | MGAT3, NF-κB, BACE1, and VDR gene expression in PBMCs from AD patients and control subjects treated with Aβ (48 h) or untreated, and
COMPOUND 2 (24 h) or COMPOUND 2 (24 h) + Aβ (24 h).
VDR, four and fivefold increase, respectively) and a decrease
in NF-κB and BACE1 (6- and 8-fold-decrease, respectively)
(Figure 6).
Effect of COMPOUND 2 Treatment on
PBMCs From AD Patients and Healthy
Volunteers
Peripheral blood mononuclear cells from 30 AD patients and 28
healthy subjects were treated with COMPOUND 2 (i.e., 0.1 µM
for 24 h) and then Aβ (i.e., 1 µM) was added to the cells for the
next 24 h.
Aβ Protein Quantification
Compared to healthy volunteers, qualitative results of
immunofluorescence and quantitative results of AlphaLISA
showed a significant decrease of Aβ (p < 0.01) in PBMCs
from AD patients treated with COMPOUND 2 (0.1 µM, 24 h)
(Figures 7A,B). No significant differences in Aβ was observed
for PBMCs from healthy volunteers treated with COMPOUND
2 although there was a slight reduction in Aβ deposits.
Gene Expression
Compared to healthy volunteers, treatment of PBMCs from AD
patients with COMPOUND 2 (i.e., 0.1 µM for 24 h) showed
transcriptional changes in 9 genes (i.e., ICAM1, FOS, IRF1,
MGAT3, VDR, TLR7, CASP8, NFKB, and BACE1, 9-, 6-, 8-,
12-, and 7-fold, increase, respectively, and 6-, 6-, 8-, and 4-fold,
decrease, respectively) (Figure 7C). Data from quantitative
RT-PCR were in accordance with NGS data described above and
with COMPOUND 2 treatment results that showed a decrease
in NF-κB and BACE1 and an increase of MGAT3 and VDR
(p< 0.01) (Figure 8).
Effect of COMPOUNDS 3–5 Treatment on
PBMCs From AD Patients and Healthy
Subjects
Peripheral blood mononuclear cells from 30 AD patients and
28 healthy volunteers were treated with COMPOUND 3 (i.e.,
0.1 µM for 24 h) and then Aβ (i.e., 1 µM) was added to cells for
the next 24 h.
Aβ Protein Quantification
Qualitative results from immunofluorescence showed a decrease
in Aβ similar to COMPOUNDS 1 and 2 (Figure 9A),
but quantitative results from AlphaLISA were less significant
(p < 0.05) than the results of COMPOUNDS 1 and 2 treatments
(Figure 9B). No significant differences in immunofluorescence
were observed in PBMCs from healthy subjects treated with
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FIGURE 9 | Peripheral blood mononuclear cells from AD patients and control subjects treated with Aβ (48 h) or untreated, COMPOUND 3 (24 h) or COMPOUND 3
(24 h) + Aβ (24 h).
COMPOUND 4 and 5, despite evidence there was a slight
decrease in Aβ deposits.
Gene Expression
COMPOUND 3 decreased gene expression of target genes
compared to COMPOUND 1 or COMPOUND 2. NGS analysis
revealed alteration in 4 genes (i.e., MGAT3, CD40, TLR8, and
PTGS2) (Figure 9C). Validation of NGS results with quantitative
RT-PCR confirmed a statistically significant (p< 0.01, p< 0.001)
increase of MGAT3 and VDR and a decrease of NF-κB and BACE1
(Figure 10).
DISCUSSION
Alzheimer’s Disease is a progressive, degenerative brain disease
that is the most common cause of dementia in elderly people. One
of the main pathogenic factors in AD includes amyloid plaques
derived from cleavage of amyloid precursor protein (APP) by
BACE1 in neurons. Moreover, it has been shown that regulation
of gene expression related to Aβ clearance is also altered in AD
(Fiala et al., 2007; Sebollela et al., 2012).
The strength of this work is the use of human PBMCs
from AD and age-matched control individuals to examine
curcuminoid effects on Aβ clearance gene regulation as anti-AD
compounds. We analyzed the protective effect of curcuminoids
and investigated two main pathways: BACE1/NF-κB and
MGAT3/VDR. The results of the studies may be relevant to
the use of curcuminoids in prevention of AD working via Aβ
clearance mechanisms. In particular, we studied how curcumins
act on cell susceptibility to Aβ accumulation. We conducted
studies that showed treatment with curcumin that may decrease
the predisposition of Aβ to accumulate into cells.
In untreated PBMCs, our data showed that, BACE1 and
NF-κB genes were up-regulated in PBMCs from AD patients
compared to PBMCs from healthy volunteers. Increases in both
BACE1 and NF-κB have been reported in AD brain (Chen et al.,
2012; Sebollela et al., 2012) but have not been described in
peripheral cells of AD patients. Chen and collaborators showed
thatNF-κB regulates BACE1with consequent toxic Aβ generation
(Chami et al., 2012). Data herein showed an increase of Aβ
1–42 in PBMCs from AD patients where corresponding elevated
levels of NF-κB and BACE1 mRNAs were present. Recently,
a NF-κB-binding element was identified in the human BACE1
promoter region (Chami et al., 2012).
MGAT3 and BACE1 working together may also be involved in
the Aβ clearance pathway: MGAT3 may regulate the degradation
of BACE1 in lysosomes (Kizuka et al., 2016). This constitutes
one important step related to Aβ-plaque formation and MGAT3
may also stabilize BACE1 in oxidative stress conditions (Hickman
et al., 2008; Palmigiano et al., 2016). Compared to PBMCs from
controls, MGAT3 and VDR have been reported to be down-
regulated in PBMCs from AD subjects (Fiala et al., 2007). In
addition, compared to healthy subjects, macrophage function is
decreased in subjects with AD (Hickman et al., 2008). An increase
of MGAT3 functional activity may improve macrophage viability,
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FIGURE 10 | MGAT3, NF-κB, BACE1, and VDR gene expression in PBMCs from AD patients and control subject treated with Aβ (48 h) and untreated, COMPOUND
3 (24 h) or COMPOUND 3 (24 h) + Aβ (24 h).
because it has been previously shown that MGAT3 silencing
inhibited Aβ phagocytic function of control monocytes.
To support the hypothesis that curcuminoids selectively
enhance Aβ phagocytosis, attenuate APP maturation and alter
gene transcription in PBMCs of AD patients we tested the
effects of curcuminoids on PBMCs from patients with AD
disease (Farmer et al., 2000; Cashman et al., 2012). In brief,
our data shows curcumin treatment (i.e., particularly BDC)
produced a decrease of intracellular Aβ aggregates, an increase
of phagocytosis (e.g., the MGAT3 pathway) and a reduction of
inflammation.
Results of treatment of PBMCs from AD patients with
curcuminoids (and subsequently treated with Aβ to induce Aβ
aggregation) showed an ability to act on cell susceptibility to Aβ
accumulation for three curcumin analogs (COMPOUNDS 1, 2,
and 3). COMPOUND 1 appeared to be the most potent.
Data herein showed NF-κB and BACE1 were decreased after
pre- with curcuminoids. Because NF-κB signaling leads to an
up-regulation of BACE1 gene expression and facilitates APP
processing in PBMCs from AD patients, its decline following
treatment would decrease the formation of Aβ fragments by
BACE1. In addition, the decrease in NF-κB leads to suppression
of the inflammatory cascade, one of the major pathways in
AD. PBMCs from AD patients treated with curcumin led to
an increase in gene expression of MGAT3, VDR, and TLR4
similar to controls. Normal elevated levels of MGAT3 have been
associated with an effective degradation and disposal process
of Aβ, although the detailed mechanism has not yet been fully
elucidated (Kizuka et al., 2015).
Vitamin D3, VDR’s endogenous ligand, regulates transcription
of genes of innate immunity (Lin, 2016). It has been
hypothesized that Vitamin D3 possesses immunostimulant
effects and also induces phagocytosis and degradation of
Aβ by monocytes/macrophages maturation (Aggarwal and
Harikumar, 2009; Masoumi et al., 2009). We suggest that
increased MGAT3 and VDR inhibit Aβ accumulation and
decreases inflammation. Moreover, in most systems, vitamin
D inhibits the activation of NF-κB (Chen et al., 2013).
VDR stimulation induced by curcuminoids could shift this
balance to and increase inhibitory activity of VDR on NF-
κB (Geldmeyer-Hilt et al., 2011). For both MGAT3 and VDR
pathways, an increase of TLR4 may also play a role in NF-κB
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repression and on macrophage activation even if it still remains
unclear what acts as a TLR4 activator.
Future work will be to identify and characterize molecular
factors of the inflammatory process and the relationships between
them. Our data support continued pharmacological studies.
In the future, curcumins may be established as important
dietary supplements in asymptomatic AD subjects (Reddy et al.,
2018). Finally, BDC may be useful in subjects that have more
propensities to develop AD or in subjects that are in the early
stages of Aβ accumulation but that is still not damaging to
prevent the degeneration to Aβ plaques, a key event in AD
pathogenesis.
CONCLUSION
The data presented herein may contribute to the understanding
of the etiopathogenetic mechanism of AD. Further studies may
be warranted to investigate a possible preventive approach
in human subjects that may be susceptible to develop AD
but that still do not have clinical signs. In a cell model,
we have shown that Treatment with curcuminoids inhibits
the pathological mechanisms that are responsible for some
AD pathways such as the activation of inflammation and of
accumulation of Aβ.
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